Colgate-Palmolive Company: Q3 2008 10-Q Summary
Business Context and Reporting Period
This filing is a Quarterly Report (Form 10-Q) for Colgate-Palmolive Company for the period ended September 30, 2008. The Company operates globally in two primary segments: Oral, Personal and Home Care, and Pet Nutrition (Hill's). The report covers the third quarter and the first nine months of 2008, comparing results to the same periods in 2007.
Key Financial Metrics
| Metric (in millions) | Q3 2008 | Q3 2007 | 9M 2008 | 9M 2007 |
|---|---|---|---|---|
| Net Sales | $3,988.0 | $3,528.2 | $11,665.8 | $10,147.5 |
| Gross Profit | $2,236.2 | $1,983.6 | $6,575.8 | $5,704.2 |
| Operating Profit | $768.4 | $668.8 | $2,259.1 | $1,977.5 |
| Net Income | $499.9 | $420.1 | $1,460.2 | $1,322.5 |
| Diluted EPS | $0.94 | $0.77 | $2.72 | $2.43 |
| Cash from Operations (9M) | $1,757.0 | $1,638.7 | ||
| Capital Expenditures (9M) | ||||
| Long-Term Debt | $3,284.4 | $3,221.9 | ||
| Cash & Equivalents |
Margins (Q3 2008 vs Q3 2007): Gross margin decreased slightly to 56.1% from 56.2%. Operating margin increased to 19.3% from 18.9%.
Material Changes vs. Prior Period
- Sales Growth: Net sales increased 13.0% in Q3 and 15.0% for the nine months ended September 30, 2008. Growth was driven by volume increases (3.0% in Q3), net selling price increases (6.5% in Q3), and favorable foreign exchange impacts (3.5% in Q3).
- Profitability: Operating profit rose 15% in Q3 and 14% for the nine-month period. This growth occurred despite higher raw material and packaging costs, which were partially offset by price increases and cost-saving initiatives.
- Restructuring: The Company continues its 2004 Restructuring Program. Pretax restructuring charges were $47.2 million in Q3 2008 (down from $51.1 million in Q3 2007) and $124.5 million for the nine months (down from $152.4 million).
- Segment Performance:
- Latin America: Sales up 21.0% in Q3; Operating profit up 25%.
- Greater Asia/Africa: Sales up 18.0% in Q3; Operating profit up 28%.
- North America: Sales up 4.5%; Operating profit decreased 4% due to higher material costs.
- Pet Nutrition: Sales up 13.0% in Q3; Operating profit up 14%.
Outlook, Risks, and Unusual Items
- Outlook: Management expects market conditions to remain challenging for the remainder of 2008 and into 2009. While the strengthening U.S. dollar is expected to negatively impact results, benefits from declining material costs and cost-savings initiatives are projected to offset currency impacts in 2009.
- Restructuring Completion: The 2004 Restructuring Program is on schedule to be completed by December 31, 2008. Cumulative pretax charges are estimated between $1,050 million and $1,075 million.
- Legal and Tax Contingencies:
- Mexico: A $670 million VAT assessment was withdrawn by authorities in October 2008. However, income tax assessments totaling approximately $885 million (including interest/penalties) regarding transfer pricing remain under dispute; the Company intends to challenge these vigorously.
- Brazil: Criminal charges against officers were dismissed in September 2008. Tax assessments related to the Kolynos acquisition (approx. $117 million) are being appealed.
- Competition Law: Investigations are ongoing in multiple European countries (France, Germany, UK, etc.). No fines have been levied against the Company to date.
- Market Risk: The Company faces risks from currency fluctuations, raw material costs, and global credit market uncertainties, though its strong credit rating currently maintains access to capital.
Investor Verification Checklist
- Restructuring Progress: Verify the remaining cash outlays required to complete the 2004 Restructuring Program by year-end 2008.
- Margin Sustainability: Monitor the ability to maintain gross margins given the volatility in raw material and commodity costs versus the effectiveness of price increases.
- Legal Exposure: Track the resolution of the Mexican transfer pricing dispute and Brazilian tax assessments, which represent significant potential liabilities if not resolved favorably.
- Foreign Exchange Impact: Assess the sensitivity of future earnings to the strengthening U.S. dollar, particularly in high-growth regions like Latin America and Greater Asia/Africa.
- Capital Allocation: Review the balance between capital expenditures (currently ~4.5% of sales), share repurchases (30 million share program), and dividend increases.